KR100806928B1 - 카르복실산, 그의 유도체 및 이들을 함유하는 약학적 조성물 - Google Patents

카르복실산, 그의 유도체 및 이들을 함유하는 약학적 조성물 Download PDF

Info

Publication number
KR100806928B1
KR100806928B1 KR1019997006147A KR19997006147A KR100806928B1 KR 100806928 B1 KR100806928 B1 KR 100806928B1 KR 1019997006147 A KR1019997006147 A KR 1019997006147A KR 19997006147 A KR19997006147 A KR 19997006147A KR 100806928 B1 KR100806928 B1 KR 100806928B1
Authority
KR
South Korea
Prior art keywords
delete delete
compounds
compound
acid
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997006147A
Other languages
English (en)
Korean (ko)
Other versions
KR20000069934A (ko
Inventor
제이콥 바-타나
Original Assignee
이쑴리서치디벨로프먼트컴파니오브더헤브류유니버시티오브예루살렘
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이쑴리서치디벨로프먼트컴파니오브더헤브류유니버시티오브예루살렘 filed Critical 이쑴리서치디벨로프먼트컴파니오브더헤브류유니버시티오브예루살렘
Publication of KR20000069934A publication Critical patent/KR20000069934A/ko
Application granted granted Critical
Publication of KR100806928B1 publication Critical patent/KR100806928B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/602—Dicarboxylic acid esters having at least two carbon-to-carbon double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019997006147A 1997-01-07 1997-12-25 카르복실산, 그의 유도체 및 이들을 함유하는 약학적 조성물 Expired - Fee Related KR100806928B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL119971 1997-01-07
IL11997197A IL119971A (en) 1997-01-07 1997-01-07 Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
PCT/IL1997/000427 WO1998030530A1 (en) 1997-01-07 1997-12-25 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077003601A Division KR100806927B1 (ko) 1997-01-07 1997-12-25 카르복실산, 그의 유도체 및 이들을 함유하는 약학적조성물

Publications (2)

Publication Number Publication Date
KR20000069934A KR20000069934A (ko) 2000-11-25
KR100806928B1 true KR100806928B1 (ko) 2008-02-22

Family

ID=11069666

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019997006147A Expired - Fee Related KR100806928B1 (ko) 1997-01-07 1997-12-25 카르복실산, 그의 유도체 및 이들을 함유하는 약학적 조성물
KR1020077003601A Expired - Fee Related KR100806927B1 (ko) 1997-01-07 1997-12-25 카르복실산, 그의 유도체 및 이들을 함유하는 약학적조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077003601A Expired - Fee Related KR100806927B1 (ko) 1997-01-07 1997-12-25 카르복실산, 그의 유도체 및 이들을 함유하는 약학적조성물

Country Status (10)

Country Link
US (3) US6284903B1 (enExample)
EP (2) EP2112134B1 (enExample)
JP (2) JP2001507713A (enExample)
KR (2) KR100806928B1 (enExample)
AT (1) ATE431816T1 (enExample)
AU (1) AU742945B2 (enExample)
CA (1) CA2277075C (enExample)
DE (1) DE69739415D1 (enExample)
IL (1) IL119971A (enExample)
WO (1) WO1998030530A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
IL119971A (en) * 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
CN1329359C (zh) 1999-04-01 2007-08-01 埃斯佩里安医疗公司 醚化合物,及其组合物和用途
EP1366024A2 (en) 2000-10-11 2003-12-03 Esperion Therapeutics Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
MXPA03003022A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de sulfuro y disulfuro y composiciones para el control del colesterol y usos relacionados.
CN1894195A (zh) 2000-10-11 2007-01-10 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的醚化合物以及组合物
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
MXPA03003020A (es) 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de cetona y composiciones para el control del colesterol y usos relacionados.
PT2404890T (pt) 2003-01-23 2017-10-23 Esperion Therapeutics Inc Compostos de hidroxilo e composições para gestão do colesterol e utilizações relacionadas
EP1701931B1 (en) 2003-12-24 2018-10-10 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US20090018199A1 (en) * 2003-12-30 2009-01-15 Syndrome X Ltd. Methods of Administering 3, 3, 14, 14 Tetramethyl Hexadecane 1, 16 Dioic Acid
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
US8053440B2 (en) 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
IL181577A0 (en) * 2007-02-26 2007-07-04 Jacob Bar Tana Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders
EP2167069B1 (en) 2007-05-23 2011-10-26 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
CA2992231C (en) 2009-03-18 2022-03-29 Resverlogix Corp. Phenyl-quinazolin-4(3h)-one and phenyl-pyrido[2,3-d]pyrimidin-4(3h)-one derivatives and compositions thereof useful as anti-inflammatory agents
MX352614B (es) 2009-04-22 2017-12-01 Resverlogix Corp Nuevos agentes anti-inflamatorios.
KR101660578B1 (ko) 2009-09-03 2016-09-27 화이자 백신스 엘엘씨 Ｐｃｓｋ９ 백신
MX2013003078A (es) 2010-09-20 2013-09-26 Kareus Therapeutics Sa Metodos y composiciones para el tratamiento de diabetes y dislipidemia.
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
HRP20191587T1 (hr) 2011-11-01 2019-12-13 Resverlogix Corp Formulacije s trenutnim oslobađanjem za oralnu primjenu supstituiranih kinazolinona
WO2013084237A1 (en) 2011-12-08 2013-06-13 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9271978B2 (en) 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
JP6940411B2 (ja) 2015-03-13 2021-09-29 エスペリオン・セラピューティクス・インコーポレイテッドＥｓｐｅｒｉｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｅｔｃ１００２及びエゼチミブを含む固定用量組合せ物及び製剤並びに心血管疾患を処置するか又は心血管疾患のリスクを低減させる方法
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
CN107118098B (zh) * 2016-02-25 2020-07-14 中国科学院上海药物研究所 一类脂肪酸类化合物、其制备方法及其用途
EP3463330B1 (en) * 2016-06-02 2022-05-04 Syndromex Ltd. Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates
US10512624B2 (en) 2016-11-30 2019-12-24 Syndromex Ltd. Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1
AU2020296094B2 (en) 2019-06-21 2025-02-06 Esperion Therapeutics, Inc. Methods of making bempedoic acid and compositions of the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) * 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) * 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US4634795A (en) * 1981-12-15 1987-01-06 Epis S.A. Long-chain α,ω-di-carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US4634975A (en) * 1984-09-17 1987-01-06 Progressive Dynamics, Inc. Method and apparatus for producing electromagnetic surveillance fields

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268082A (en) 1969-08-08 1972-03-22 Orsymonde Improvements in or relating to bis-(carboxy-alkylene-thio)-decanes
BE755550A (fr) * 1969-09-02 1971-02-01 Parke Davis & Co Acides alcanedioiques, leurs sels et leurs esters abaissant la teneur en triglycerides du serum sanguin
FR2288516A2 (fr) * 1974-10-21 1976-05-21 Orsymonde Nouveaux bis-(carboxyalcoylene-thio)-1,10 decanes et leurs derives
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
JPS61171417A (ja) * 1985-01-23 1986-08-02 Wakunaga Seiyaku Kk 抗糖尿病剤
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3634356A1 (de) * 1986-10-08 1988-04-21 Epis Sa Arzneimittel enthaltend alpha-halogenierte dicarbonsaeuren
DE4224670A1 (de) * 1992-07-25 1994-01-27 Boehringer Mannheim Gmbh Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
IL119971A (en) * 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
JP2003001549A (ja) * 2001-06-26 2003-01-08 Howa Mach Ltd 光電式刃具折れ検知装置

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) * 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) * 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US4634795A (en) * 1981-12-15 1987-01-06 Epis S.A. Long-chain α,ω-di-carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US4689344A (en) * 1981-12-15 1987-08-25 Epis S.A. Long-chain α,ω-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US4634975A (en) * 1984-09-17 1987-01-06 Progressive Dynamics, Inc. Method and apparatus for producing electromagnetic surveillance fields

Also Published As

Publication number Publication date
EP2112134A1 (en) 2009-10-28
KR20000069934A (ko) 2000-11-25
CA2277075A1 (en) 1998-07-16
EP0988274B1 (en) 2009-05-20
KR20070026888A (ko) 2007-03-08
CA2277075C (en) 2010-06-22
IL119971A0 (en) 1997-04-15
EP0988274A4 (en) 2000-10-18
KR100806927B1 (ko) 2008-02-22
ATE431816T1 (de) 2009-06-15
US20040132818A1 (en) 2004-07-08
AU7994798A (en) 1998-08-03
DE69739415D1 (de) 2009-07-02
IL119971A (en) 2003-02-12
EP2112134B1 (en) 2013-10-30
JP2001507713A (ja) 2001-06-12
US20020049345A1 (en) 2002-04-25
US6284903B1 (en) 2001-09-04
JP2010077141A (ja) 2010-04-08
JP5479857B2 (ja) 2014-04-23
WO1998030530A1 (en) 1998-07-16
EP0988274A1 (en) 2000-03-29
AU742945B2 (en) 2002-01-17
US6800772B2 (en) 2004-10-05

Similar Documents

Publication Publication Date Title
KR100806928B1 (ko) 카르복실산, 그의 유도체 및 이들을 함유하는 약학적 조성물
US4634795A (en) Long-chain α,ω-di-carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US6245814B1 (en) Diphenylethylene compounds
IE851502L (en) Derivatives of glutamic and aspartic acid
AU778767B2 (en) Novel diphenylethylene compounds
US3637803A (en) Alkyl methylsulfonylalkyl benzoates
JPH0432073B2 (enExample)
EP2226329B1 (en) Metal-containing platensimycin analogues
JPH0729923B2 (ja) カスタノスペルミン抗糖尿病剤
CA2487165C (en) Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease
AU780162B2 (en) Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
KR20030070137A (ko) 항스트레스제
JP2954989B2 (ja) ビスフェノール誘導体での真性糖尿病処置法
DE2151720A1 (de) Arzneimittel zur Bekaempfung von Virusinfektionen und seine Verwendung als Zusatz zu Tierfutterkonzentraten
MXPA99006358A (en) Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS607999B2 (ja) パラアミノ安息香酸誘導体および該誘導体を含有する医薬
US4457941A (en) Use of pyrrolo-pyrrole in treating microvascular diseases associated with diabetes
SU1015622A1 (ru) 2-Замещенные 3-окси-5-метил-4-тиофенуксусные кислоты,обладающие противовоспалительной и анальгетической активностью и способ их получени
JPH0323526B2 (enExample)
BE875451A (fr) Nouveaux medicaments constitues de derives de l'acide p-amino-benzoique
DE2430077A1 (de) Derivate von phenylessigsaeure, verfahren zu ihrer herstellung und sie enthaltende arzneimittelzubereitungen
JPH072675B2 (ja) 鎌状赤血球貧血の治療に有用な化合物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20110714

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20120219

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20120219